2024-09-28 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance Comparison:**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) over the period analyzed. LLY's cumulative return is 879.52%, while VOO's is 134.22%, resulting in a return difference of **745.3**. This difference places LLY's performance at the **92.48th percentile** of its historical range, indicating a strong outperformance compared to the benchmark.

**2. Recent Price Movements:**

LLY's closing price is **$909.32**. The stock is trading below its 5-day moving average ($919.18) and 20-day moving average ($922.26), suggesting potential downward pressure. However, it is above its 60-day moving average ($899.06), indicating a longer-term upward trend. 

**3. Technical Indicators:**

* **RSI (52.81):** The stock is currently in neutral territory, indicating neither overbought nor oversold conditions.
* **PPO (-0.26):** The negative PPO value suggests potential downward momentum, although it is relatively close to zero, implying a weaker signal.
* **Delta_Previous_Relative_Divergence (-6.73):** The negative value indicates a recent decline in the stock's relative performance.
* **Expected_Return (6.08%):** This represents the estimated maximum potential return over the next 5 years based on current investment levels. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings report (2024-08-08) showed a positive EPS of 3.29, exceeding analyst estimates. Revenue also grew to 11.30 B$, demonstrating strong growth in the company's performance.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Eli Lilly and Co (LLY) has recently benefited from strong demand for its key products, such as its diabetes medications and treatments for Alzheimer's disease. This positive market outlook has contributed to the company's impressive performance.
* **Analyst Opinions:** Many analysts remain optimistic about LLY's future prospects, citing the company's strong pipeline of innovative drugs and its robust financial position.
* **Performance Highlights:** Eli Lilly and Co (LLY) has been recognized for its consistent growth and innovation, earning accolades for its commitment to research and development. 

**6. Overall Analysis:**

Eli Lilly and Co (LLY) presents a compelling investment opportunity. The company has consistently outperformed the market, driven by strong earnings and positive market dynamics. While recent price movements suggest potential downward pressure, its strong long-term growth prospects and favorable market conditions make it a promising investment. However, it's important to monitor its technical indicators and recent news to assess its short-term performance.

**7. Report Summary:**

This report highlights the strong performance of Eli Lilly and Co (LLY) relative to the S&P 500 (VOO). The company has delivered significant returns and is poised for continued growth, driven by its innovative drug pipeline and strong financials. While technical indicators suggest a potential near-term decline, the long-term outlook for LLY remains positive. 
